Novartis data confirms rapid response of Cosentyx® in China study
Category: #health  By Mateen Dalal  Date: 2019-03-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

Novartis data confirms rapid response of Cosentyx® in China study

The study proves to offer clear or almost clear skin in 8/10 patients within 16 weeks of Cosentyx® 300mg treatment.

Swiss pharmaceutical major, Novartis AG (NVS) has recently announced that its data from a Phase III study conducted on 441 Chinese patients with moderate to severe plaque psoriasis confirmed rapid response and high efficiency of Cosentyx®.

For the record, Cosentyx® is a biological and the first and only treatment that specifically prevents IL-17A, a messenger protein involved in the development of psoriatic disease, including psoriatic arthritis (PsA), psoriasis (PsO) and ankylosing spondylitis (AS).

According to sources, the data, being part of a larger ongoing 52-week Phase III study in 543 patients, showed that around 9/10 patients subjected to Cosentyx® 300mg achieved clear or near clear skin during the first 16 weeks of treatment, with rapid relief attained as early as 3 weeks.

The company said that Cosentyx® is backed by a wealth of research with 100 studies and has been proven to offer clear or nearly clear skin in 8/10 patients within 16 weeks of treatment. Nearly 100% of response rates are maintained up to 5 years.

According to a press release, Eric Hughes, Head of Global Development Unit, Immunology, Hepatology & Dermatology, and Head of China Region Development, Novartis, said that Cosentyx® continues to meet the needs of psoriasis patients, reimagining care to provide clear skin and a complete treatment.

He said that the company is excited to report its data for the first-time for the Chinese population and to see strong support from the data for Cosentyx®.

For the record, Cosentyx® has demonstarted fast and sustained long-term efficacy, besides a consistent favorable safety profile, with almost zero injection pain and site reactions. It is approved in over 80 countries, which includes the EU countries and the U.S., and is supported by 100 studies in the real world and clinical settings.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

SpringWorks begins Phase 3 trial of desmoid tumor treatment in adults
SpringWorks begins Phase 3 trial of desmoid tumor treatment in adults
By Mateen Dalal

The company is looking forward to enrolling patients with desmoid tumors to confirm the clinical benefits of nirogacestat SpringWorks Therapeutics, a clinical-stage biopharmaceutical company, has reportedly announced the beginning of Phase 3 “...

Exelixis & Iconic Therapeutics ink exclusive license and option deal
Exelixis & Iconic Therapeutics ink exclusive license and option deal
By Mateen Dalal

The exclusive license & option agreement has been signed for a new Antibody-Drug conjugate program.   The program, named ICON-2, specifically targets Tissue Factor and would have a potential broad impact on oncology. Exelixis, Inc., (E...

JD.com invests $55 million to foster connected vehicle fleets
JD.com invests $55 million to foster connected vehicle fleets
By Mateen Dalal

The launch of logistic service has begun to reap early rewards regarding cost saving. The long-time rival of Alibaba and Amazon, JD.com, has reportedly announced to invest 376 million yuan (around $55 million) in Jiangsu Xinning Modern Logistics to ...